Company Filing History:
3 out of 4 
1 out of 1 
1 out of 182 Years Active: 2020-2025
Title: **Inventor Yi-Hong Wu: Innovating Cancer Treatment**
Introduction
Yi-Hong Wu, a prominent inventor based in Taipei, Taiwan, has made significant contributions to cancer research through his innovative inventions. With a total of five patents to his name, Wu's work focuses on developing compounds that play a crucial role in the tumor microenvironment and offer new avenues for cancer therapy.
Latest Patents
Among Yi-Hong Wu's latest patents are notable inventions that incorporate advanced medical chemistry. The first patent, titled "Histone Deacetylase Inhibitors for Immunomodulation in Tumor Microenvironment," relates to class I HDAC inhibitors. These compounds exhibit epigenetic immunomodulatory activities that inhibit tumor cell growth, thereby showcasing their potential in cancer treatment. The second patent, "Anticancer Combination of Chidamide and Celecoxib Salts," introduces a combination therapy that synergizes the effects of a histone deacetylase inhibitor, chidamide, and a nonsteroidal anti-inflammatory drug, celecoxib. This combination significantly regulates the tumor microenvironment, enhancing the overall anti-cancer effectiveness.
Career Highlights
Yi-Hong Wu has worked with several notable companies in the biotech and medical sectors, including Great Novel Therapeutics and GNT Biotech and Medical Corporation. His experiences in these organizations have allowed him to deepen his understanding of medical innovations, positioning him as a key figure in the field of cancer therapeutics.
Collaborations
Collaboration plays a vital role in Wu's career. He has worked alongside esteemed colleagues like Chia-Nan Chen and Ye-Su Chao, allowing for an exchange of ideas and knowledge that enriches his research. Their joint efforts have contributed to advancing the efficacy of cancer treatment approaches.
Conclusion
Yi-Hong Wu stands out as an influential inventor in the realm of cancer research. His innovations, reflected in his patents, reveal a commitment to developing advanced treatment options that can significantly improve patient outcomes. As the field of immunotherapy evolves, Wu's contributions will likely continue to shape the future of cancer treatment.